A chronic lung infection with Pseudomonas aeruginosa is associated with an increased exacerbation and mortality rate in people affected by bronchiectasis. Inhaled antibiotics are frequently used in clinical practice to treat chronic infections with this bacterium. The PROMIS-I and PROMIS-II studies investigated the efficacy and safety of 12-month inhaled colistimethate sodium administration in patients with bronchiectasis and chronic P. aeruginosa infection.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Doing sport without fear or risk
Doing sport without fear or risk
- Chronic inducible urticaria
What has stayed the same, what has changed?
- Blastic plasmacytoid dendritic cell neoplasia
Rare malignancy from a dermatological perspective
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Glomerulonephritis: IgA nephropathy
Pathogenesis-based and nephroprotective therapeutic approaches
- Case report: Acute rheumatic fever
ARF with myocarditis and occlusion of the RCA
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Internal thoracoscopy